COMPARISON OF METFORMIN AND CYPROTERONE-ESTRODIOL COMPOUND EFFECT ON HS C-REACTIVE PROTEIN AND SERUM ANDROGEN LEVELS IN PATIENTS WITH POLY CYSTIC OVARY SYNDROME

Abstract

Objectives: The aim of this study was comparison of the effects of Metformin and Cyproterone-estradiol compound on serum androgens & highly sensitive C-reactive protein levels. Methodology: Sixty patients with Poly Cystic Ovary Syndrome (PCOS) were enrolled in this study conducted during a period of 16 months from December 2004 to March 2006. Thirty subjects were in each group and treated with Metformin one gram per day or Cyproterone-estradiol compound 21 days monthly and at the beginning and after 3 and 6 months, weight, height, testosterone, dehydroepiandrosterone sulfate (DHEA-S) and hs-CRP levels were measured. Results: Mean age of patients was 23.5 +/- 8.7 years with the range of 15 to 49 years. In both groups significant decreases in DHEA-S levels and in Cyproterone-estradiol compound group a significant decrease in testosterone levels were seen after 6 months, but there were no significant decrease on hs- CRP levels. Comparison of two groups showed that there were no significant differences in the effects of these two drugs on serum testosterone, DHEA-S and hs-CRP levels. In our study the level of hs- CRP at the beginning of treatment were significantly higher in patients who were overweight and obese. Also we found that Cyproterone-estradiol compound causes significant decrease at the level of hs-CRP in overweight and obese patients. Conclusion: The results of this study are different from those of previous studies about beneficial effects of Metformin on hs-CRP levels but are similar to the results of studies that revealed probably obesity and overweight has important role in inducing inflammation and increasing CRP levels.